286 related articles for article (PubMed ID: 8939755)
1. Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity.
Rutenber EE; Stroud RM
Structure; 1996 Nov; 4(11):1317-24. PubMed ID: 8939755
[TBL] [Abstract][Full Text] [Related]
2. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition.
Stout TJ; Stroud RM
Structure; 1996 Jan; 4(1):67-77. PubMed ID: 8805515
[TBL] [Abstract][Full Text] [Related]
3. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug.
Phan J; Koli S; Minor W; Dunlap RB; Berger SH; Lebioda L
Biochemistry; 2001 Feb; 40(7):1897-902. PubMed ID: 11329255
[TBL] [Abstract][Full Text] [Related]
4. D221 in thymidylate synthase controls conformation change, and thereby opening of the imidazolidine.
Sage CR; Michelitsch MD; Stout TJ; Biermann D; Nissen R; Finer-Moore J; Stroud RM
Biochemistry; 1998 Sep; 37(39):13893-901. PubMed ID: 9753479
[TBL] [Abstract][Full Text] [Related]
5. Cofactor triggers the conformational change in thymidylate synthase: implications for an ordered binding mechanism.
Kamb A; Finer-Moore JS; Stroud RM
Biochemistry; 1992 Dec; 31(51):12876-84. PubMed ID: 1281428
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP.
Almog R; Waddling CA; Maley F; Maley GF; Van Roey P
Protein Sci; 2001 May; 10(5):988-96. PubMed ID: 11316879
[TBL] [Abstract][Full Text] [Related]
7. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
8. Structure, multiple site binding, and segmental accommodation in thymidylate synthase on binding dUMP and an anti-folate.
Montfort WR; Perry KM; Fauman EB; Finer-Moore JS; Maley GF; Hardy L; Maley F; Stroud RM
Biochemistry; 1990 Jul; 29(30):6964-77. PubMed ID: 2223754
[TBL] [Abstract][Full Text] [Related]
9. Role of an invariant lysine residue in folate binding on Escherichia coli thymidylate synthase: calorimetric and crystallographic analysis of the K48Q mutant.
Arvizu-Flores AA; Sugich-Miranda R; Arreola R; Garcia-Orozco KD; Velazquez-Contreras EF; Montfort WR; Maley F; Sotelo-Mundo RR
Int J Biochem Cell Biol; 2008; 40(10):2206-17. PubMed ID: 18403248
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug.
Sotelo-Mundo RR; Ciesla J; Dzik JM; Rode W; Maley F; Maley GF; Hardy LW; Montfort WR
Biochemistry; 1999 Jan; 38(3):1087-94. PubMed ID: 9894005
[TBL] [Abstract][Full Text] [Related]
11. Kinetic scheme for thymidylate synthase from Escherichia coli: determination from measurements of ligand binding, primary and secondary isotope effects, and pre-steady-state catalysis.
Spencer HT; Villafranca JE; Appleman JR
Biochemistry; 1997 Apr; 36(14):4212-22. PubMed ID: 9100016
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
Aherne GW; Hardcastle A; Raynaud F; Jackman AL
Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of thymidylate synthase mutant R166Q: structural basis for the nearly complete loss of catalytic activity.
Sotelo-Mundo RR; Changchien L; Maley F; Montfort WR
J Biochem Mol Toxicol; 2006; 20(2):88-92. PubMed ID: 16615077
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
[TBL] [Abstract][Full Text] [Related]
15. Crystal structures of a marginally active thymidylate synthase mutant, Arg 126-->Glu.
Strop P; Changchien L; Maley F; Montfort WR
Protein Sci; 1997 Dec; 6(12):2504-11. PubMed ID: 9416600
[TBL] [Abstract][Full Text] [Related]
16. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.
Jackman AL; Boyle FT; Harrap KR
Invest New Drugs; 1996; 14(3):305-16. PubMed ID: 8958186
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for recognition of polyglutamyl folates by thymidylate synthase.
Kamb A; Finer-Moore J; Calvert AH; Stroud RM
Biochemistry; 1992 Oct; 31(41):9883-90. PubMed ID: 1390771
[TBL] [Abstract][Full Text] [Related]
18. The structural mechanism for half-the-sites reactivity in an enzyme, thymidylate synthase, involves a relay of changes between subunits.
Anderson AC; O'Neil RH; DeLano WL; Stroud RM
Biochemistry; 1999 Oct; 38(42):13829-36. PubMed ID: 10529228
[TBL] [Abstract][Full Text] [Related]
19. An essential role for water in an enzyme reaction mechanism: the crystal structure of the thymidylate synthase mutant E58Q.
Sage CR; Rutenber EE; Stout TJ; Stroud RM
Biochemistry; 1996 Dec; 35(50):16270-81. PubMed ID: 8973201
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
